uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study
Univ Gothenburg, Dept Endocrinol, Sahlgrenska Acad, Inst Med, Gothenburg, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
Shire Int GmbH, Zug, Switzerland..
Shire PLC, Wayne, PA USA..
Show others and affiliations
2016 (English)In: European Journal of Endocrinology, ISSN 0804-4643, E-ISSN 1479-683X, Vol. 175, no 1, 85-93 p.Article in journal (Refereed) PublishedText
Abstract [en]

Objective: Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy was developed to provide a cortisol exposure-time profile that closely resembles the physiological cortisol profile. This study aimed to characterize single-dose pharmacokinetics (PK) of DR-HC 5-20 mg and assess intrasubject variability. Methods: Thirty-one healthy Japanese or non-Hispanic Caucasian volunteers aged 20-55 years participated in this randomized, open-label, PK study. Single doses of DR-HC 5, 15 (3 x 5), and 20 mg were administered orally after an overnight fast and suppression of endogenous cortisol secretion. After estimating the endogenous cortisol profile, PK of DR-HC over 24 h were evaluated to assess dose proportionality and impact of ethnicity. Plasma cortisol concentrations were analyzed using liquid chromatography-tandem mass spectrometry. PK parameters were calculated from individual cortisol concentration-time profiles. Results: DR-HC 20 mg provided higher than endogenous cortisol plasma concentrations 0-4 h post-dose but similar concentrations later in the profile. Cortisol concentrations and PK exposure parameters increased with increasing doses. Mean maximal serum concentration (C-max) was 82.0 and 178.1 ng/mL, while mean area under the concentration-time curve (AUC)(0-infinity) was 562.8 and 1180.8 h x ng/mL with DR-HC 5 and 20 mg respectively. Within-subject PK variability was low (<15%) for DR-HC 20 mg. All exposure PK parameters were less than dose proportional (slope < 1). PK differences between ethnicities were explained by body weight differences. Conclusions: DR-HC replacement resembles the daily normal cortisol profile. Within-subject day-to-day PK variability was low, underpinning the safety of DR-HC for replacement therapy. DR-HC PK were less than dose proportional - an important consideration when managing intercurrent illness in patients with adrenal insufficiency.

Place, publisher, year, edition, pages
2016. Vol. 175, no 1, 85-93 p.
National Category
Endocrinology and Diabetes
URN: urn:nbn:se:uu:diva-299837DOI: 10.1530/EJE-15-1212ISI: 000378754700014PubMedID: 27129362OAI: oai:DiVA.org:uu-299837DiVA: diva2:950288
Available from: 2016-07-29 Created: 2016-07-28 Last updated: 2016-07-29Bibliographically approved

Open Access in DiVA

fulltext(797 kB)12 downloads
File information
File name FULLTEXT01.pdfFile size 797 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lennernäs, Hans
By organisation
Department of Pharmacy
In the same journal
European Journal of Endocrinology
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 12 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 18 hits
ReferencesLink to record
Permanent link

Direct link